---
title: Metabolism Des LAM
nct_id: NCT02176109
overall_status: UNKNOWN
sponsor: University Hospital, Grenoble
study_type: OBSERVATIONAL
primary_condition: Iron
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02176109.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02176109"
ct_last_update_post_date: 2014-06-26
last_seen_at: "2026-05-12T06:36:29.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Metabolism Des LAM

**Official Title:** Rôle Pronostique Des métabolismes du Stress Oxydatif et du Fer Dans Les Leucémies Aiguës Myéloblastiques

**NCT ID:** [NCT02176109](https://clinicaltrials.gov/study/NCT02176109)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** University Hospital, Grenoble
- **Conditions:** Iron, Acute Myeloid Leukemia, Diagnosis, Oxydative Stress
- **Start Date:** 2013-06
- **Completion Date:** 2018-06
- **CT.gov Last Update:** 2014-06-26

## Brief Summary

In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.

## Detailed Description

Primary goal of this study is to Evaluate the characteristics of regulatory networks of iron and redox balance in leukemic cells, to study the correlations between the prognosis of AML patients (in terms of response to induction chemotherapy and survival i) and metabolism of these markers. Secondary ones areto assess the impact of induction therapy on markers of oxidative stress and to correlate biological iron and redox metabolism with the molecular status of patients (eg Flt3/IDH/CEBPA/NPM...).

Eligibility criteria are patients at diagnostic of de novo acute myeloid leukemia (promyelocytic excluded) aged from 18 to 100 years.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

de novo acute myeloid leukemic patient from 18 years to 99 years at diagnosis

Exclusion Criteria:

age under 18 years promelocytic leukemia secondary leukemia
```

## Primary Outcomes

- **overall survival Event-free survival Response to induction chemotherapy, overalll survival, event-free survival** _(time frame: five years after the inclusion)_

## Locations (1)

- University Hospital Grenoble, Grenoble, Isere, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university hospital grenoble|grenoble|isere|france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02176109.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02176109*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*